These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 12387055)

  • 1. [SGLT inhibitor (T-1095)].
    Saito A; Seiyaku T; Tsujihara K
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():588-93. PubMed ID: 12387055
    [No Abstract]   [Full Text] [Related]  

  • 2. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095.
    Arakawa K; Ishihara T; Oku A; Nawano M; Ueta K; Kitamura K; Matsumoto M; Saito A
    Br J Pharmacol; 2001 Jan; 132(2):578-86. PubMed ID: 11159708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats.
    Nunoi K; Yasuda K; Adachi T; Okamoto Y; Shihara N; Uno M; Tamon A; Suzuki N; Oku A; Tsuda K
    Clin Exp Pharmacol Physiol; 2002; 29(5-6):386-90. PubMed ID: 12010180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihyperglycemic effect of T-1095 via inhibition of renal Na+-glucose cotransporters in streptozotocin-induced diabetic rats.
    Oku A; Ueta K; Arakawa K; Kano-Ishihara T; Matsumoto M; Adachi T; Yasuda K; Tsuda K; Saito A
    Biol Pharm Bull; 2000 Dec; 23(12):1434-7. PubMed ID: 11145172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats.
    Ueta K; Ishihara T; Matsumoto Y; Oku A; Nawano M; Fujita T; Saito A; Arakawa K
    Life Sci; 2005 Apr; 76(23):2655-68. PubMed ID: 15792833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Sodium-Glucose Transporters as a Therapeutic Target for Diabetes from the Viewpoint of Drug Discovery and Pharmacotherapy].
    Miyamoto L; Tsuchiya K
    Yakugaku Zasshi; 2018; 138(7):933-938. PubMed ID: 29962472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction of hyperglycemia and insulin sensitivity by T-1095, an inhibitor of renal Na+-glucose cotransporters, in streptozotocin-induced diabetic rats.
    Oku A; Ueta K; Arakawa K; Kano-Ishihara T; Matsumoto T; Adachi T; Yasuda K; Tsuda K; Ikezawa K; Saito A
    Jpn J Pharmacol; 2000 Nov; 84(3):351-4. PubMed ID: 11138738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrazole-O-glucosides as novel Na(+)-glucose cotransporter (SGLT) inhibitors.
    Ohsumi K; Matsueda H; Hatanaka T; Hirama R; Umemura T; Oonuki A; Ishida N; Kageyama Y; Maezono K; Kondo N
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2269-72. PubMed ID: 12824015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes.
    Oku A; Ueta K; Arakawa K; Ishihara T; Nawano M; Kuronuma Y; Matsumoto M; Saito A; Tsujihara K; Anai M; Asano T; Kanai Y; Endou H
    Diabetes; 1999 Sep; 48(9):1794-800. PubMed ID: 10480610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperglycemia contributes insulin resistance in hepatic and adipose tissue but not skeletal muscle of ZDF rats.
    Nawano M; Oku A; Ueta K; Umebayashi I; Ishirahara T; Arakawa K; Saito A; Anai M; Kikuchi M; Asano T
    Am J Physiol Endocrinol Metab; 2000 Mar; 278(3):E535-43. PubMed ID: 10710509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidative stress and glucose metabolism--is there a need to revisit effects of insulin treatment?
    Humpert PM
    Diabetologia; 2010 Mar; 53(3):403-5. PubMed ID: 20052454
    [No Abstract]   [Full Text] [Related]  

  • 12. [The cutting-edge of medicine; novel therapeutic agents for the treatment of diabetes sodium-glucose co-transporter (SGLT) 2 inhibitors].
    Sugimoto T; Kashiwagi A
    Nihon Naika Gakkai Zasshi; 2013 Jun; 102(6):1474-83. PubMed ID: 23947218
    [No Abstract]   [Full Text] [Related]  

  • 13. Hyperglycemia impairs the insulin signaling step between PI 3-kinase and Akt/PKB activations in ZDF rat liver.
    Nawano M; Ueta K; Oku A; Arakawa K; Saito A; Funaki M; Anai M; Kikuchi M; Oka Y; Asano T
    Biochem Biophys Res Commun; 1999 Dec; 266(1):252-6. PubMed ID: 10581198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
    Grempler R; Thomas L; Eckhardt M; Himmelsbach F; Sauer A; Sharp DE; Bakker RA; Mark M; Klein T; Eickelmann P
    Diabetes Obes Metab; 2012 Jan; 14(1):83-90. PubMed ID: 21985634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Achieving better control of blood sugar--understanding of oral hypoglycemic agents according to their characteristics in pharmacological action mechanism (discussion)].
    Kawamori R; Kadowaki T; Ishida H
    Nihon Rinsho; 2004 Apr; 62(4):831-9. PubMed ID: 15106356
    [No Abstract]   [Full Text] [Related]  

  • 16. Reduction of renal transport maximum for glucose by inhibition of NA(+)-glucose cotransporter suppresses blood glucose elevation in dogs.
    Ueta K; Yoneda H; Oku A; Nishiyama S; Saito A; Arakawa K
    Biol Pharm Bull; 2006 Jan; 29(1):114-8. PubMed ID: 16394522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New therapeutic approaches in type II diabetes].
    Reach G
    Journ Annu Diabetol Hotel Dieu; 1993; ():155-60. PubMed ID: 8331862
    [No Abstract]   [Full Text] [Related]  

  • 18. [Glucocorticoid-induced diabetes].
    Ogawa Y; Tomotsune K; Suda T
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():324-8. PubMed ID: 15779396
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
    Washburn WN
    J Med Chem; 2009 Apr; 52(7):1785-94. PubMed ID: 19243175
    [No Abstract]   [Full Text] [Related]  

  • 20. [Insulin secretion in the clinical stages of diabetes (with glucose tolerance test abnormalities)].
    Vague P; Vague J
    Journ Annu Diabetol Hotel Dieu; 1972; 13(0):55-65. PubMed ID: 4605752
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.